{"entity":{"type":"insider","cik":"0001758363","url":"/insider/0001758363","json_url":"/insider/0001758363.json","name":"Turtle Cameron","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":77,"n_filings":34,"first":"2019-06-06","last":"2026-08-05","span_basis":"filed_date"},"name_variants":[{"name":"Turtle Cameron","source":"filing","n_filings":34,"first_seen":"2019-06-06","last_seen":"2026-08-05"}],"transactions":[{"id":5875297,"accession":"0001636282-26-000099","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001636282-26-000099","line_url":"/filing/0001636282-26-000099#line-5","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7157.0,"shares_display":"7,157","price_per_share":95.1,"price_display":"95.10","price_state":"stated","total_value":680630.7,"total_display":"680,630.70","shares_owned_after":574583.0,"shares_owned_after_display":"574,583","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-03","filed_date":"2026-08-05","scope":"insider"},{"id":5875293,"accession":"0001636282-26-000099","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001636282-26-000099","line_url":"/filing/0001636282-26-000099#line-4","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5635.0,"shares_display":"5,635","price_per_share":95.93,"price_display":"95.93","price_state":"stated","total_value":540565.55,"total_display":"540,565.55","shares_owned_after":568948.0,"shares_owned_after_display":"568,948","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-03","filed_date":"2026-08-05","scope":"insider"},{"id":5875292,"accession":"0001636282-26-000099","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001636282-26-000099","line_url":"/filing/0001636282-26-000099#line-3","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1392.0,"shares_display":"1,392","price_per_share":96.82,"price_display":"96.82","price_state":"stated","total_value":134773.44,"total_display":"134,773.44","shares_owned_after":567556.0,"shares_owned_after_display":"567,556","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-03","filed_date":"2026-08-05","scope":"insider"},{"id":5875289,"accession":"0001636282-26-000099","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001636282-26-000099","line_url":"/filing/0001636282-26-000099#line-2","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":800.0,"shares_display":"800","price_per_share":93.97,"price_display":"93.97","price_state":"stated","total_value":75176.0,"total_display":"75,176.00","shares_owned_after":581740.0,"shares_owned_after_display":"581,740","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-03","filed_date":"2026-08-05","scope":"insider"},{"id":5875286,"accession":"0001636282-26-000099","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001636282-26-000099","line_url":"/filing/0001636282-26-000099#line-1","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16.0,"shares_display":"16","price_per_share":97.46,"price_display":"97.46","price_state":"stated","total_value":1559.36,"total_display":"1,559.36","shares_owned_after":567540.0,"shares_owned_after_display":"567,540","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-03","filed_date":"2026-08-05","scope":"insider"},{"id":5827940,"accession":"0001636282-26-000086","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001636282-26-000086","line_url":"/filing/0001636282-26-000086#line-3","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10176.0,"shares_display":"10,176","price_per_share":87.44,"price_display":"87.44","price_state":"stated","total_value":889789.44,"total_display":"889,789.44","shares_owned_after":587364.0,"shares_owned_after_display":"587,364","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-01","filed_date":"2026-07-02","scope":"insider"},{"id":5827939,"accession":"0001636282-26-000086","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001636282-26-000086","line_url":"/filing/0001636282-26-000086#line-2","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4234.0,"shares_display":"4,234","price_per_share":88.12,"price_display":"88.12","price_state":"stated","total_value":373100.08,"total_display":"373,100.08","shares_owned_after":583130.0,"shares_owned_after_display":"583,130","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-01","filed_date":"2026-07-02","scope":"insider"},{"id":5827937,"accession":"0001636282-26-000086","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001636282-26-000086","line_url":"/filing/0001636282-26-000086#line-1","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":590.0,"shares_display":"590","price_per_share":88.91,"price_display":"88.91","price_state":"stated","total_value":52456.9,"total_display":"52,456.90","shares_owned_after":582540.0,"shares_owned_after_display":"582,540","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-01","filed_date":"2026-07-02","scope":"insider"},{"id":5910147,"accession":"0001636282-26-000077","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001636282-26-000077","line_url":"/filing/0001636282-26-000077#line-3","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8149.0,"shares_display":"8,149","price_per_share":70.5,"price_display":"70.50","price_state":"stated","total_value":574504.5,"total_display":"574,504.50","shares_owned_after":600834.0,"shares_owned_after_display":"600,834","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-01","filed_date":"2026-06-03","scope":"insider"},{"id":5910146,"accession":"0001636282-26-000077","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001636282-26-000077","line_url":"/filing/0001636282-26-000077#line-2","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3557.0,"shares_display":"3,557","price_per_share":69.4,"price_display":"69.40","price_state":"stated","total_value":246855.8,"total_display":"246,855.80","shares_owned_after":608983.0,"shares_owned_after_display":"608,983","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-01","filed_date":"2026-06-03","scope":"insider"},{"id":5910145,"accession":"0001636282-26-000077","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001636282-26-000077","line_url":"/filing/0001636282-26-000077#line-1","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3294.0,"shares_display":"3,294","price_per_share":71.38,"price_display":"71.38","price_state":"stated","total_value":235125.72,"total_display":"235,125.72","shares_owned_after":597540.0,"shares_owned_after_display":"597,540","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-01","filed_date":"2026-06-03","scope":"insider"},{"id":6115244,"accession":"0001758363-26-000009","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001758363-26-000009","line_url":"/filing/0001758363-26-000009#line-6","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5300.0,"shares_display":"5,300","price_per_share":69.54,"price_display":"69.54","price_state":"stated","total_value":368562.0,"total_display":"368,562.00","shares_owned_after":622240.0,"shares_owned_after_display":"622,240","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-01","filed_date":"2026-05-01","scope":"insider"},{"id":6115241,"accession":"0001758363-26-000009","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001758363-26-000009","line_url":"/filing/0001758363-26-000009#line-5","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3600.0,"shares_display":"3,600","price_per_share":70.77,"price_display":"70.77","price_state":"stated","total_value":254772.0,"total_display":"254,772.00","shares_owned_after":618640.0,"shares_owned_after_display":"618,640","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-01","filed_date":"2026-05-01","scope":"insider"},{"id":6115239,"accession":"0001758363-26-000009","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001758363-26-000009","line_url":"/filing/0001758363-26-000009#line-4","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3100.0,"shares_display":"3,100","price_per_share":73.14,"price_display":"73.14","price_state":"stated","total_value":226734.0,"total_display":"226,734.00","shares_owned_after":614540.0,"shares_owned_after_display":"614,540","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-01","filed_date":"2026-05-01","scope":"insider"},{"id":6115236,"accession":"0001758363-26-000009","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001758363-26-000009","line_url":"/filing/0001758363-26-000009#line-3","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1700.0,"shares_display":"1,700","price_per_share":74.23,"price_display":"74.23","price_state":"stated","total_value":126191.0,"total_display":"126,191.00","shares_owned_after":612840.0,"shares_owned_after_display":"612,840","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-01","filed_date":"2026-05-01","scope":"insider"},{"id":6115234,"accession":"0001758363-26-000009","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001758363-26-000009","line_url":"/filing/0001758363-26-000009#line-2","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":71.76,"price_display":"71.76","price_state":"stated","total_value":71760.0,"total_display":"71,760.00","shares_owned_after":617640.0,"shares_owned_after_display":"617,640","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-01","filed_date":"2026-05-01","scope":"insider"},{"id":6115230,"accession":"0001758363-26-000009","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001758363-26-000009","line_url":"/filing/0001758363-26-000009#line-1","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":300.0,"shares_display":"300","price_per_share":74.96,"price_display":"74.96","price_state":"stated","total_value":22488.0,"total_display":"22,488.00","shares_owned_after":612540.0,"shares_owned_after_display":"612,540","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-01","filed_date":"2026-05-01","scope":"insider"},{"id":6199675,"accession":"0001758363-26-000007","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001758363-26-000007","line_url":"/filing/0001758363-26-000007#line-2","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12344.0,"shares_display":"12,344","price_per_share":49.2,"price_display":"49.20","price_state":"stated","total_value":607324.8,"total_display":"607,324.80","shares_owned_after":630196.0,"shares_owned_after_display":"630,196","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-01","filed_date":"2026-04-03","scope":"insider"},{"id":6199671,"accession":"0001758363-26-000007","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001758363-26-000007","line_url":"/filing/0001758363-26-000007#line-1","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2656.0,"shares_display":"2,656","price_per_share":49.92,"price_display":"49.92","price_state":"stated","total_value":132587.52,"total_display":"132,587.52","shares_owned_after":627540.0,"shares_owned_after_display":"627,540","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-01","filed_date":"2026-04-03","scope":"insider"},{"id":5848399,"accession":"0001636282-26-000026","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001636282-26-000026","line_url":"/filing/0001636282-26-000026#line-2","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9100.0,"shares_display":"9,100","price_per_share":42.49,"price_display":"42.49","price_state":"stated","total_value":386659.0,"total_display":"386,659.00","shares_owned_after":642540.0,"shares_owned_after_display":"642,540","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-02","filed_date":"2026-03-03","scope":"insider"},{"id":5848398,"accession":"0001636282-26-000026","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001636282-26-000026","line_url":"/filing/0001636282-26-000026#line-1","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5900.0,"shares_display":"5,900","price_per_share":41.73,"price_display":"41.73","price_state":"stated","total_value":246207.0,"total_display":"246,207.00","shares_owned_after":651640.0,"shares_owned_after_display":"651,640","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-02","filed_date":"2026-03-03","scope":"insider"},{"id":5988672,"accession":"0001758363-26-000005","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001758363-26-000005","line_url":"/filing/0001758363-26-000005#line-2","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14043.0,"shares_display":"14,043","price_per_share":32.87,"price_display":"32.87","price_state":"stated","total_value":461593.41,"total_display":"461,593.41","shares_owned_after":657540.0,"shares_owned_after_display":"657,540","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-02","filed_date":"2026-02-04","scope":"insider"},{"id":5988669,"accession":"0001758363-26-000005","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001758363-26-000005","line_url":"/filing/0001758363-26-000005#line-1","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":957.0,"shares_display":"957","price_per_share":31.82,"price_display":"31.82","price_state":"stated","total_value":30451.74,"total_display":"30,451.74","shares_owned_after":671583.0,"shares_owned_after_display":"671,583","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-02","filed_date":"2026-02-04","scope":"insider"},{"id":6061370,"accession":"0001758363-26-000002","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001758363-26-000002","line_url":"/filing/0001758363-26-000002#line-3","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12709.0,"shares_display":"12,709","price_per_share":30.47,"price_display":"30.47","price_state":"stated","total_value":387243.23,"total_display":"387,243.23","shares_owned_after":674198.0,"shares_owned_after_display":"674,198","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-02","filed_date":"2026-01-06","scope":"insider"},{"id":6061368,"accession":"0001758363-26-000002","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001758363-26-000002","line_url":"/filing/0001758363-26-000002#line-2","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2191.0,"shares_display":"2,191","price_per_share":31.79,"price_display":"31.79","price_state":"stated","total_value":69651.89,"total_display":"69,651.89","shares_owned_after":672007.0,"shares_owned_after_display":"672,007","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-02","filed_date":"2026-01-06","scope":"insider"},{"id":6061365,"accession":"0001758363-26-000002","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001758363-26-000002","line_url":"/filing/0001758363-26-000002#line-1","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100.0,"shares_display":"100","price_per_share":32.39,"price_display":"32.39","price_state":"stated","total_value":3239.0,"total_display":"3,239.00","shares_owned_after":671907.0,"shares_owned_after_display":"671,907","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-02","filed_date":"2026-01-06","scope":"insider"},{"id":4684817,"accession":"0001758363-25-000003","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001758363-25-000003","line_url":"/filing/0001758363-25-000003#line-2","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10995.0,"shares_display":"10,995","price_per_share":28.73,"price_display":"28.73","price_state":"stated","total_value":315886.35,"total_display":"315,886.35","shares_owned_after":690912.0,"shares_owned_after_display":"690,912","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-01","filed_date":"2025-12-03","scope":"insider"},{"id":4684811,"accession":"0001758363-25-000003","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001758363-25-000003","line_url":"/filing/0001758363-25-000003#line-1","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4005.0,"shares_display":"4,005","price_per_share":29.83,"price_display":"29.83","price_state":"stated","total_value":119469.15,"total_display":"119,469.15","shares_owned_after":686907.0,"shares_owned_after_display":"686,907","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-01","filed_date":"2025-12-03","scope":"insider"},{"id":5202494,"accession":"0001636282-25-000106","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001636282-25-000106","line_url":"/filing/0001636282-25-000106#line-2","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":28155.0,"shares_display":"28,155","price_per_share":23.13,"price_display":"23.13","price_state":"stated","total_value":651225.15,"total_display":"651,225.15","shares_owned_after":718752.0,"shares_owned_after_display":"718,752","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-03","filed_date":"2025-11-05","scope":"insider"},{"id":5202491,"accession":"0001636282-25-000106","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001636282-25-000106","line_url":"/filing/0001636282-25-000106#line-1","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16845.0,"shares_display":"16,845","price_per_share":23.66,"price_display":"23.66","price_state":"stated","total_value":398552.7,"total_display":"398,552.70","shares_owned_after":701907.0,"shares_owned_after_display":"701,907","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-03","filed_date":"2025-11-05","scope":"insider"},{"id":3320322,"accession":"0000899243-20-035444","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000899243-20-035444","line_url":"/filing/0000899243-20-035444#line-5","is_derivative":false,"issuer_cik":"0001743881","issuer_name":"BridgeBio Pharma, Inc.","issuer_ticker":"BBIO","issuer_name_source":null,"issuer_url":"/issuer/0001743881","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Officer","officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10937.0,"shares_display":"10,937","price_per_share":69.3361,"price_display":"69.34","price_state":"stated","total_value":758328.9257,"total_display":"758,328.93","shares_owned_after":21131.0,"shares_owned_after_display":"21,131","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-12-28","filed_date":"2020-12-29","scope":"insider"},{"id":3320317,"accession":"0000899243-20-035444","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-20-035444","line_url":"/filing/0000899243-20-035444#line-4","is_derivative":false,"issuer_cik":"0001743881","issuer_name":"BridgeBio Pharma, Inc.","issuer_ticker":"BBIO","issuer_name_source":null,"issuer_url":"/issuer/0001743881","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Officer","officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8563.0,"shares_display":"8,563","price_per_share":69.9352,"price_display":"69.94","price_state":"stated","total_value":598855.1176,"total_display":"598,855.12","shares_owned_after":12568.0,"shares_owned_after_display":"12,568","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-12-28","filed_date":"2020-12-29","scope":"insider"},{"id":2462626,"accession":"0000899243-20-034181","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-20-034181","line_url":"/filing/0000899243-20-034181#line-6","is_derivative":false,"issuer_cik":"0001731831","issuer_name":"Eidos Therapeutics, Inc.","issuer_ticker":"EIDX","issuer_name_source":null,"issuer_url":"/issuer/0001731831","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11445.0,"shares_display":"11,445","price_per_share":112.1903,"price_display":"112.19","price_state":"stated","total_value":1284017.9835,"total_display":"1,284,017.98","shares_owned_after":54114.0,"shares_owned_after_display":"54,114","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-12-15","filed_date":"2020-12-16","scope":"insider"},{"id":2462622,"accession":"0000899243-20-034181","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000899243-20-034181","line_url":"/filing/0000899243-20-034181#line-5","is_derivative":false,"issuer_cik":"0001731831","issuer_name":"Eidos Therapeutics, Inc.","issuer_ticker":"EIDX","issuer_name_source":null,"issuer_url":"/issuer/0001731831","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7600.0,"shares_display":"7,600","price_per_share":111.3075,"price_display":"111.31","price_state":"stated","total_value":845937.0,"total_display":"845,937.00","shares_owned_after":65559.0,"shares_owned_after_display":"65,559","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-12-15","filed_date":"2020-12-16","scope":"insider"},{"id":2462618,"accession":"0000899243-20-034181","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-20-034181","line_url":"/filing/0000899243-20-034181#line-4","is_derivative":false,"issuer_cik":"0001731831","issuer_name":"Eidos Therapeutics, Inc.","issuer_ticker":"EIDX","issuer_name_source":null,"issuer_url":"/issuer/0001731831","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3756.0,"shares_display":"3,756","price_per_share":110.2906,"price_display":"110.29","price_state":"stated","total_value":414251.4936,"total_display":"414,251.49","shares_owned_after":73159.0,"shares_owned_after_display":"73,159","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-12-15","filed_date":"2020-12-16","scope":"insider"},{"id":2462614,"accession":"0000899243-20-034181","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-20-034181","line_url":"/filing/0000899243-20-034181#line-3","is_derivative":false,"issuer_cik":"0001731831","issuer_name":"Eidos Therapeutics, Inc.","issuer_ticker":"EIDX","issuer_name_source":null,"issuer_url":"/issuer/0001731831","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3493.0,"shares_display":"3,493","price_per_share":112.9657,"price_display":"112.97","price_state":"stated","total_value":394589.1901,"total_display":"394,589.19","shares_owned_after":50621.0,"shares_owned_after_display":"50,621","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-12-15","filed_date":"2020-12-16","scope":"insider"},{"id":2045297,"accession":"0000899243-20-032234","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-20-032234","line_url":"/filing/0000899243-20-032234#line-4","is_derivative":false,"issuer_cik":"0001743881","issuer_name":"BridgeBio Pharma, Inc.","issuer_ticker":"BBIO","issuer_name_source":null,"issuer_url":"/issuer/0001743881","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Officer","officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":742.0,"shares_display":"742","price_per_share":47.2288,"price_display":"47.23","price_state":"stated","total_value":35043.7696,"total_display":"35,043.77","shares_owned_after":12568.0,"shares_owned_after_display":"12,568","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-25","filed_date":"2020-11-25","scope":"insider"},{"id":2045295,"accession":"0000899243-20-032234","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-032234","line_url":"/filing/0000899243-20-032234#line-2","is_derivative":false,"issuer_cik":"0001743881","issuer_name":"BridgeBio Pharma, Inc.","issuer_ticker":"BBIO","issuer_name_source":null,"issuer_url":"/issuer/0001743881","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Officer","officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4258.0,"shares_display":"4,258","price_per_share":47.0026,"price_display":"47.00","price_state":"stated","total_value":200137.0708,"total_display":"200,137.07","shares_owned_after":12568.0,"shares_owned_after_display":"12,568","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-24","filed_date":"2020-11-25","scope":"insider"},{"id":3033491,"accession":"0000899243-20-031006","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-20-031006","line_url":"/filing/0000899243-20-031006#line-4","is_derivative":false,"issuer_cik":"0001731831","issuer_name":"Eidos Therapeutics, Inc.","issuer_ticker":"EIDX","issuer_name_source":null,"issuer_url":"/issuer/0001731831","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9497.0,"shares_display":"9,497","price_per_share":74.7457,"price_display":"74.75","price_state":"stated","total_value":709859.9129,"total_display":"709,859.91","shares_owned_after":53029.0,"shares_owned_after_display":"53,029","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-11","filed_date":"2020-11-13","scope":"insider"},{"id":3033488,"accession":"0000899243-20-031006","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-20-031006","line_url":"/filing/0000899243-20-031006#line-3","is_derivative":false,"issuer_cik":"0001731831","issuer_name":"Eidos Therapeutics, Inc.","issuer_ticker":"EIDX","issuer_name_source":null,"issuer_url":"/issuer/0001731831","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3005.0,"shares_display":"3,005","price_per_share":73.564,"price_display":"73.56","price_state":"stated","total_value":221059.82,"total_display":"221,059.82","shares_owned_after":62526.0,"shares_owned_after_display":"62,526","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-11","filed_date":"2020-11-13","scope":"insider"},{"id":3033485,"accession":"0000899243-20-031006","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-031006","line_url":"/filing/0000899243-20-031006#line-2","is_derivative":false,"issuer_cik":"0001731831","issuer_name":"Eidos Therapeutics, Inc.","issuer_ticker":"EIDX","issuer_name_source":null,"issuer_url":"/issuer/0001731831","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":908.0,"shares_display":"908","price_per_share":75.2286,"price_display":"75.23","price_state":"stated","total_value":68307.5688,"total_display":"68,307.57","shares_owned_after":52121.0,"shares_owned_after_display":"52,121","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-11","filed_date":"2020-11-13","scope":"insider"},{"id":3167681,"accession":"0000899243-20-030623","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-030623","line_url":"/filing/0000899243-20-030623#line-2","is_derivative":false,"issuer_cik":"0001743881","issuer_name":"BridgeBio Pharma, Inc.","issuer_ticker":"BBIO","issuer_name_source":null,"issuer_url":"/issuer/0001743881","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Officer","officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":42.0499,"price_display":"42.05","price_state":"stated","total_value":105124.75,"total_display":"105,124.75","shares_owned_after":12568.0,"shares_owned_after_display":"12,568","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-05","filed_date":"2020-11-09","scope":"insider"},{"id":2732798,"accession":"0000899243-20-030216","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000899243-20-030216","line_url":"/filing/0000899243-20-030216#line-5","is_derivative":false,"issuer_cik":"0001731831","issuer_name":"Eidos Therapeutics, Inc.","issuer_ticker":"EIDX","issuer_name_source":null,"issuer_url":"/issuer/0001731831","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9145.0,"shares_display":"9,145","price_per_share":70.4438,"price_display":"70.44","price_state":"stated","total_value":644208.551,"total_display":"644,208.55","shares_owned_after":68886.0,"shares_owned_after_display":"68,886","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-02","filed_date":"2020-11-03","scope":"insider"},{"id":2732790,"accession":"0000899243-20-030216","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-20-030216","line_url":"/filing/0000899243-20-030216#line-4","is_derivative":false,"issuer_cik":"0001731831","issuer_name":"Eidos Therapeutics, Inc.","issuer_ticker":"EIDX","issuer_name_source":null,"issuer_url":"/issuer/0001731831","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3146.0,"shares_display":"3,146","price_per_share":71.4167,"price_display":"71.42","price_state":"stated","total_value":224676.9382,"total_display":"224,676.94","shares_owned_after":65740.0,"shares_owned_after_display":"65,740","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-02","filed_date":"2020-11-03","scope":"insider"},{"id":2732787,"accession":"0000899243-20-030216","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-20-030216","line_url":"/filing/0000899243-20-030216#line-3","is_derivative":false,"issuer_cik":"0001731831","issuer_name":"Eidos Therapeutics, Inc.","issuer_ticker":"EIDX","issuer_name_source":null,"issuer_url":"/issuer/0001731831","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Officer (Chief Business Officer)","officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":209.0,"shares_display":"209","price_per_share":72.0961,"price_display":"72.10","price_state":"stated","total_value":15068.0849,"total_display":"15,068.08","shares_owned_after":65531.0,"shares_owned_after_display":"65,531","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-02","filed_date":"2020-11-03","scope":"insider"},{"id":3319726,"accession":"0000899243-20-026978","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000899243-20-026978","line_url":"/filing/0000899243-20-026978#line-5","is_derivative":false,"issuer_cik":"0001743881","issuer_name":"BridgeBio Pharma, Inc.","issuer_ticker":"BBIO","issuer_name_source":null,"issuer_url":"/issuer/0001743881","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Officer","officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12442.0,"shares_display":"12,442","price_per_share":37.5945,"price_display":"37.59","price_state":"stated","total_value":467750.769,"total_display":"467,750.77","shares_owned_after":14626.0,"shares_owned_after_display":"14,626","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-09-30","filed_date":"2020-10-02","scope":"insider"},{"id":3319722,"accession":"0000899243-20-026978","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-20-026978","line_url":"/filing/0000899243-20-026978#line-4","is_derivative":false,"issuer_cik":"0001743881","issuer_name":"BridgeBio Pharma, Inc.","issuer_ticker":"BBIO","issuer_name_source":null,"issuer_url":"/issuer/0001743881","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Officer","officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2058.0,"shares_display":"2,058","price_per_share":38.2444,"price_display":"38.24","price_state":"stated","total_value":78706.9752,"total_display":"78,706.98","shares_owned_after":12568.0,"shares_owned_after_display":"12,568","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-09-30","filed_date":"2020-10-02","scope":"insider"},{"id":2987095,"accession":"0000899243-20-025962","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-025962","line_url":"/filing/0000899243-20-025962#line-2","is_derivative":false,"issuer_cik":"0001743881","issuer_name":"BridgeBio Pharma, Inc.","issuer_ticker":"BBIO","issuer_name_source":null,"issuer_url":"/issuer/0001743881","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Officer","officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":42.0097,"price_display":"42.01","price_state":"stated","total_value":105024.25,"total_display":"105,024.25","shares_owned_after":12568.0,"shares_owned_after_display":"12,568","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-09-18","filed_date":"2020-09-22","scope":"insider"},{"id":2732354,"accession":"0000899243-20-025366","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-025366","line_url":"/filing/0000899243-20-025366#line-2","is_derivative":false,"issuer_cik":"0001743881","issuer_name":"BridgeBio Pharma, Inc.","issuer_ticker":"BBIO","issuer_name_source":null,"issuer_url":"/issuer/0001743881","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Officer","officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":37.0607,"price_display":"37.06","price_state":"stated","total_value":92651.75,"total_display":"92,651.75","shares_owned_after":12568.0,"shares_owned_after_display":"12,568","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-09-15","filed_date":"2020-09-16","scope":"insider"},{"id":2593472,"accession":"0000899243-20-025095","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-025095","line_url":"/filing/0000899243-20-025095#line-2","is_derivative":false,"issuer_cik":"0001743881","issuer_name":"BridgeBio Pharma, Inc.","issuer_ticker":"BBIO","issuer_name_source":null,"issuer_url":"/issuer/0001743881","owner_cik":"0001758363","owner_name":"Turtle Cameron","owner_url":"/insider/0001758363","role":"Officer","officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":35.0235,"price_display":"35.02","price_state":"stated","total_value":70047.0,"total_display":"70,047.00","shares_owned_after":12568.0,"shares_owned_after_display":"12,568","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-09-11","filed_date":"2020-09-15","scope":"insider"}],"next_cursor":"2020-09-11|2593472","ledger_fault":false,"count":{"value":77,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":77,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":77},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001636282","name":"Spyre Therapeutics, Inc.","url":"/issuer/0001636282","role":"Director, Officer (Chief Executive Officer)","n_filings":10,"first_seen":"2025-11-05","last_seen":"2026-08-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001743881","name":"BridgeBio Pharma, Inc.","url":"/issuer/0001743881","role":"Officer","n_filings":12,"first_seen":"2020-01-10","last_seen":"2020-12-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001731831","name":"Eidos Therapeutics, Inc.","url":"/issuer/0001731831","role":"Officer (Chief Business Officer)","n_filings":12,"first_seen":"2019-06-06","last_seen":"2020-12-16"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001758363","retrieved_at":"2026-08-21T18:31:06+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}